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Abstract
Enhanced NRG1-ERBB4 signaling is a risk pathway in schizophre-
nia, and corresponding mouse models display several endopheno-
types of the disease. Nonetheless, pathway-directed treatment
strategies with clinically applicable compounds have not been
identified. Here, we applied a cell-based assay using the split TEV
technology to screen a library of clinically applicable compounds
to identify modulators of NRG1-ERBB4 signaling for repurposing.
We recovered spironolactone, known as antagonist of corticos-
teroids, as an inhibitor of the ERBB4 receptor and tested it in
pharmacological and biochemical assays to assess secondary
compound actions. Transgenic mice overexpressing Nrg1 type III
display cortical Erbb4 hyperphosphorylation, a condition observed
in postmortem brains from schizophrenia patients. Spironolac-
tone treatment reverted hyperphosphorylation of activated Erbb4
in these mice. In behavioral tests, spironolactone treatment of
Nrg1 type III transgenic mice ameliorated schizophrenia-relevant
behavioral endophenotypes, such as reduced sensorimotor gating,
hyperactivity, and impaired working memory. Moreover, spirono-
lactone increases spontaneous inhibitory postsynaptic currents in
cortical slices supporting an ERBB4-mediated mode-of-action.
Our findings suggest that spironolactone, a clinically safe drug,
provides an opportunity for new treatment options for
schizophrenia.
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Introduction
Schizophrenia (SZ) is as severely debilitating neuropsychiatric disor-
der characterized by positive symptoms, that is, hallucinations and
delusions, negative symptoms, that is, lack of motivation, and
cognitive symptoms (Insel, 2010). Positive symptoms can frequently
be ameliorated by treatment with dopamine receptor antagonists,
but efficient treatment options for negative and cognitive symptoms
are not available (Goff et al, 2011). Thus, there is a strong clinical
need to develop and explore more target-directed therapies for SZ
(Nestler & Hyman, 2010). Repurposing of existing drugs principally
offers a fast track to the clinic and has been demanded for SZ (Insel,
2012; Lencz & Malhotra, 2015), also because many pharma compa-
nies withdrew from research on severe mental disorders (Margraf &
Schneider, 2016). Genetic association studies have identified NRG1
and its cognate receptor ERBB4 as SZ risk genes, and altered NRG-
ERBB4 signaling has been associated with positive, negative, and
cognitive symptoms (Stefansson et al, 2002; Harrison & Law, 2006;
Li et al, 2006; Nicodemus et al, 2006). Several postmortem studies
revealed increased expression of NRG1 in SZ patients (Hashimoto
et al, 2004; Law et al, 2006; Weickert et al, 2012). Elevated expres-
sion of the ERBB4-JM-a-CYT-1 variant carrying a PI3K-recruitment
domain has also been detected in SZ (Silberberg et al, 2006;
Law et al, 2007, 2012). Moreover, ERBB4 was found to be
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hyperphosphorylated in postmortem brains from SZ patients (Hahn
et al, 2006), suggesting that NRG1-ERBB4 hyperstimulation might
represent a component of SZ pathophysiology.
In agreement, transgenic mice with increased Nrg1 expression
display SZ-relevant behavioral deficits, including hyperactivity,
impaired sensorimotor gating, decreased social interaction, and
reduced cognitive functions (Deakin et al, 2009, 2012; Kato et al,
2010). In particular, transgenic mice with neuronal overexpression of
the membrane-bound cysteine-rich-domain (CRD) type III isoform of
Nrg1 (Nrg1-tg) display chronic ErbB4 hyperphosphorylation in the
cortex, which is associated with a broad spectrum of SZ-relevant
endophenotypes, including dysbalanced excitatory and inhibitory
neurotransmission, altered spine growth, and impaired sensorimotor
gating (Agarwal et al, 2014). Moreover, it has been shown recently
that endophenotypes associated with elevated Nrg1 expression are
reversible in adult animals, which strongly supports the assumption
that the NRG1/ERBB4 signaling system provides a valid target for
pharmacological interventions (Yin et al, 2013; Luo et al, 2014). It thus
appears plausible that compounds, which can re-balance the activity of
the NRG1-ERBB4 signaling pathway, could represent candidates for
the therapeutic treatment of schizophrenia beyond positive symptoms.
In this study, we have first developed a co-culture assay system
compatible with high-throughput-screening (HTS) utilizing the split
TEV technology (Wehr et al, 2006, 2008). We then used this assay
to screen a library of clinically approved drugs in a repurposing
approach to uncover new potential target specificities (Wang &
Zhang, 2013), which resulted in the identification and validation of
spironolactone as an inhibitor of ERBB4. Finally, we can show that
spironolactone decreases phosphorylation levels of ERBB4 in vitro
and in vivo and leads to an altered balance of excitation/inhibition
of cortical projection neurons. Chronic spironolactone treatment
ameliorates hyperactivity and reverses sensorimotor gating and
working memory deficits in Nrg1-tg mice. Thus, spironolactone alle-
viates novel aspects of SZ-relevant symptoms in this mouse model
of increased NRG1-ERBB4 signaling.
Results
A split TEV-based co-culture assay to screen for modulators of
NRG1-ERBB4 signaling
Screening for modulators of NRG1-ERBB4 signaling in cell culture
requires an adequate setup reflecting endogenous signaling mecha-
nisms. According to a current model, NRG1 ligands reside in presy-
naptic terminals of principle pyramidal neurons, whereas ERBB4
receptors are mainly expressed at the postsynaptic density of
dendrites in inhibitory interneurons (Rico & Marı´n, 2011). Based on
this ligand-receptor configuration, NRG1 mediates juxtacrine and
paracrine signaling to ERBB4. We established a cellular HTS-compa-
tible co-culture assay, in which NRG1 was expressed in the signal-
sending cell population A, whereas ERBB4 was expressed in the
signal-receiving cell population B (Fig 1A). Initially, we used the full-
length NRG1 type I b1a isoform that undergoes proteolytic cleavage
resulting in the release of the extracellular domain, which contains
the biologically active EGF-like domain (EGFld), into the extracellular
space (Hu et al, 2006; Willem et al, 2006). Therefore, NRG1 type I
b1a can elicit juxtacrine (non-cleaved form) and paracrine (cleaved
form) stimuli. To screen for approved small compounds that could
modulate NRG1-ERBB4 signaling, we combined this co-culture assay
with the split TEV protein–protein interaction technique to monitor
ERBB4 activation through induced PI3K adaptor recruitment by the
human ERBB4-JMa-Cyt1 variant (Fig 1A).
The functionality and robustness of the co-culture assay was
investigated by co-plating increasing numbers of PC12 cells carrying
a stably integrated mouse Nrg1 type I b1a expression cassette (Nrg1
cells, Fig EV1A for stable Nrg1 expression) with ERBB4-PIK3R1-
expressing PC12 cells (split TEV assay cells). Co-culture conditions
were verified using two PC12 cell populations expressing either
EYFP or ECFP (Fig EV1B). A dose–response analysis showed that
the assay reached a plateau of activation when 10,000 Nrg1-
expressing cells were co-plated with 40,000 split TEV assay cells,
with half-maximal activation at 5,000 cells (Fig 1B). Calculation of
the Z’ factor, a measure of HTS applicability and quality (Zhang
et al, 1999), resulted in a value of 0.5 indicating a large separation
band at screening conditions. Importantly, addition of the soluble
EGFld resulted in a twofold increase of ERBB4 activation compared
with Nrg1 cells alone, implying that ERBB4 activation in the co-
culture assay can be decreased and increased by potential NRG1-
ERBB4 inhibitors and activators, respectively (Fig 1C). In addition,
dose–response assays using ERBB4-PIK3R1 split TEV assay cells
only and soluble EGFld as stimulus (single-culture assay) showed
stable and reproducible dose–responses that also qualified for HTS,
with Z’ factors between 0.56 and 0.68 for three independent assays
(Fig EV1C). The specificity of the NRG1-ERBB4 co-culture assay
was validated in dose–response assays using established ERBB4
inhibitors, such as lapatinib (IC50 value at 2.61 lM, co-culture
assay, Fig 1D; 0.45 lM, single-culture assay, Fig EV1D) and CI-1033
(IC50 value at 0.01 lM, co-culture assay, Fig EV1E; 0.004 lM,
single-culture assay, Fig EV1F). Taken together, these data indicate
that the split TEV-based co-culture assay provides a robust platform
to screen for modulators of NRG1-ERBB4 signaling.
Screening the NIH clinical compound collection recovers
spironolactone as ERBB4 receptor antagonist
We used the split TEV-based NRG1-ERBB4-PIK3R1 co-culture assay
to screen two sets of the NIH Clinical Collection (NIH-NCC) contain-
ing 727 FDA-approved drugs in total (Fig 2A). From this screen, we
selected a primary hit list of candidates that were at least three stan-
dard deviations away from the mean (Fig 2B for NIH-NCC set 1;
Fig EV2A for NIH-NCC set 2; Dataset EV1). These candidates were
then subjected to individual re-screening to eliminate off-target
effects, such as toxicity and interference with assay tools, and 18
substances met these criteria and were selected for the final hit list
(Appendix Fig S1 for a flowchart of all screening and validation
steps; see Appendix Table S1 for final hit list). Spironolactone, a
mineralocorticoid receptor (MR) antagonist formerly used as a
diuretic and to treat high blood pressure (Gaddam et al, 2010), was
recovered as top antagonist candidate (Fig 2B). In a dose–response
co-culture assay using Nrg1 type I b1a, spironolactone displayed an
IC50 value of 1.0 lM, and marginal toxic effects at higher concentra-
tions, as indicated by reduced Renilla luciferase readings (Fig 2C).
ERBB4-specific effects were confirmed by dose–response control
assays, which showed absence of spironolactone effects on assay
components (Fig EV2B and C).
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Importantly, spironolactone also inhibited ERBB4 activity (IC50
value of 1.1 lM) in a co-culture assay using the membrane-bound CRD
containing type III isoform of Nrg1, the major NRG1 isoform in the
brain, which is implicated in juxtacrine signaling (Fig 2D). Thus,
spironolactone modulates ERBB4 activity downstream from both para-
crine and juxtacrine NRG1 signaling. Further, spironolactone acts at a
proximal step of ERBB4 receptor activation upstream of tyrosine phos-
phorylation and adapter recruitment as ERBB4 dimerization stimulated
by EGFld was efficiently inhibited (IC50 value of 1.1 lM) in a single-
culture assay (Fig 2E). Finally, we used an ERBB4 variant that lacks the
intracellular domain, and thus is signaling incompetent, but expresses
at the cell cortex and dimerizes upon EGFld stimulation (Fig EV3A and
B). Notably, spironolactone inhibits dimerization of full-length ERBB4,
but not of C-terminally truncated ERBB4 (Fig EV3C).
Spironolactone but not its metabolic products antagonizes the
ERBB4/PIK3R1 assay
Spironolactone also inhibited ERBB4 signaling activity in an ERBB4-
PIK3R1 single-culture assay, albeit with a slightly increased IC50
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Figure 1. A co-culture assay based on the split TEV technique for monitoring NRG1-ERBB4 signaling activity.
A The ERBB4-PIK3R1 split TEV assay monitors NRG1-ERBB4 signaling in PC12 cells. The Nrg1 ligand (green) is stably expressed in the signal-sending cell population A.
The signal-receiving cell population B (or split TEV assay cells) is transfected with plasmids encoding the assay components ERBB4 (red) fused to NTEV-tevS-GV
(ERBB4-NTEV-tevS-GV), the adapter molecule PIK3R1 (purple, the regulatory subunit alpha of the PI3K) fused to CTEV (PIK3R1-CTEV), and a UAS-driven firefly
luciferase reporter (Fluc). Upon Nrg1 binding to the extracellular domain of ERBB4 (1), ERBB4-NTEV-tevS-GV dimerizes and cross-phosphorylates itself (2). PIK3R1-
CTEV binds to the phosphorylated ERBB4 receptor leading to the functional reconstitution of TEV protease activity and the concomitant release of the artificial co-
transcriptional activator Gal4-VP16 (GV) through proteolytic cleavage at a TEV protease cleavage site (tevS) (3). In turn, released GV translocates to the nucleus and
binds to UAS sequences (open box) to activate the transcription of a firefly reporter gene (4).
B Dose–response assay using increasing numbers of Nrg1 type I b1a-expressing PC12 cells. For each 96-well, 40,000 split TEV assay cells were co-plated with increasing
numbers of Nrg1-expressing cells and incubated for 24 h. Half-maximal activation is reached at 5,000 Nrg1-expressing cells. The Z’ factor is 0.5 indicating a large
separation band for this assay.
C Adding 10 ng/ml EGFld resulted in a twofold activation. Per 96-well, 40,000 split TEV assay cells were co-plated with empty PC12 cells (no Nrg1 expression), 10,000
Nrg1-expressing cells, and 10,000 Nrg1-expressing cells plus 10 ng/ml EGFld. Arrows indicate measuring window of activation (blue arrow) and inhibition (red arrow)
relative to baseline activity.
D Lapatinib antagonizes ERBB4-PIK3R1 signaling in a dose-dependent manner. Per 96-well, 40,000 split TEV assay cells were incubated with increasing amounts of
lapatinib, followed by co-plating 10,000 Nrg1 type I b1a-expressing cells. The inset depicts the IC50 value in lM.
Data information: After compound/stimulus addition, each assay was incubated for 24 h. RLU, relative luciferase units; Fluc, firefly luciferase activity (black line); Rluc,
Renilla luciferase activity (gray line); n = 6; data are shown as mean, and error bars represent SEM.
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Figure 2. Spironolactone is the primary candidate recovered from the co-culture screen.
A Flow chart of the compound screen. PC12 cells (population A) were transfected in solution with the split TEV assay plasmids ERBB4-NTEV-tevS-GV and PIK3R1-
CTEV and incubated for 2 h before seeded onto 96-well plates. Population A cells were allowed to express the plasmids for 24 h. Compounds were added in a
concentration of 10 lM, followed by seeding the Nrg1-expressing PC12 cells (population B) half an hour later. After 24 h of compound incubation, cells were lysed
and subjected to a dual luciferase assay. The screening data were analyzed using the cellHTS2 package in R Bioconductor.
B Graphic visualization of the primary screen data of the NIH-NCC library set 1. All counts (320 compounds and 64 controls) from the Nrg1-ERBB4-PIK3R1 split TEV
compound screen were plotted against the Z-score using the Mondrian program, with pathway activators displaying high values and inhibitors low values. For the
secondary analysis, we selected all candidates that were at least three standard deviations away from the mean. EGFld-positive and lapatinib/CI-1033-negative
controls are shown in red.
C, D Spironolactone antagonizes Nrg1-ERBB4-PIK3R1 signaling. In dose–response assays using ERBB4-NTEV-tevS-GV and PIK3R1-CTEV plasmids transfected into PC12
cells, spironolactone was administered at increasing concentrations before seeding (C) Nrg1 type I- or (D) Nrg1 type III-expressing PC12 cells.
E Spironolactone inhibits ERBB4 receptor dimerization. Dose-dependent dimerization of the ERBB4 receptor was analyzed using a split TEV assay encompassing
ERBB4-NTEV-tevS-GV and ERBB4-CTEV plasmids transfected into PC12 cells. 10 ng/ml EGFld was applied as Nrg1 stimulus.
Data information: Fluc, firefly luciferase activity (black lines); Rluc, Renilla luciferase activity (gray lines, indicating toxicity levels); n = 6; data are shown as mean, and
error bars represent SEM. The insets depict IC50 values in lM.
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value of 2.8 lM (Fig 3A). We used the assay to identify molecular
structures in spironolactone (Fig 3A) required for the inhibition of
ERBB receptor activation in this assay and examined structurally
highly related compounds, such as the metabolites canrenone
(Fig 3B) and 7a-thiomethyl-spironolactone (Fig 3C) as well as the
second-generation MR antagonist eplerenone (Fig 3D). Canrenone
lacks the thio-ketone group attached to the sterol core structure,
whereas 7a-thiomethyl-spironolactone lacks the ketone group only.
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Figure 3. Multilevel profiling approach of spironolactone treatment assessing target specificities and adapter recruitment.
A Spironolactone, molecular structure shown on the left, inhibits ERBB4/PIK3R1 split TEV assay activity (black line), with an IC50 value of 2.76 lM.
B–D The spironolactone metabolites (B) canrenone and (C) 7a-thiomethyl-spironolactone as well as the second-generation drug (D) eplerenone do not attenuate the
ERBB4/PIK3R1 assay activity (black lines). Note that only spironolactone bears a thio-ketone group attached to the sterol core structure. All ERBB4/PIK3R1 assays
were run in a single-culture assay mode using 10 ng/ml EGFld as functional Nrg1 stimulus, and ERBB4-NTEV-tevS-GV and PIK3R1-CTEV plasmids were transfected
into PC12 cells (indicated by icon).
E Schematic representation of the most critical ERBB dimers tested in spironolactone dose–response assays using the split TEV protein–protein interaction detection
technique. Note that not all possible combinations are depicted.
F Heat map showing the IC50 values obtained from individual ERBB dimerization split TEV assays. All single dose–response assays can be found in Fig EV4; the
combination ERBB4-ERBB4 is shown in Fig 2E.
Data information: Fluc, firefly luciferase activity (black lines, reporting ERBB4-PIK3R1 assay activity); Rluc, Renilla luciferase activity (gray lines, assessing viability); n = 6;
data are shown as mean, and error bars represent SEM. The insets depict IC50 values in lM.
EMBO Molecular Medicine Vol 9 | No 10 | 2017 ª 2017 The Authors
EMBO Molecular Medicine Spironolactone inhibits NRG1-ERBB4 signaling Michael C Wehr et al
1452
In eplerenone, the thio-ketone group is replaced by an acidic group,
in addition to a minor modification at the sterol core structure.
None of these compounds showed an inhibitory effect in the
ERBB4-PIK3R1 single-culture assay (Fig 3B–D), suggesting that the
thio-ketone group specific for spironolactone plays a role for its
inhibitory function in this assay.
Spironolactone preferentially inhibits dimers containing ERBB4
Target specificity is a crucial aspect for the evaluation of pharmaco-
logical active compounds (Feng et al, 2009). As ERBB4 is a member
of the ERBB family, we determined spironolactone’s antagonistic
effects on dimer formation of other ERBB receptors (Fig 3E). As
indicated by IC50 values obtained from dose–response assays
(Figs 3F and EV4A–I), spironolactone preferentially inhibits forma-
tion of ERBB4 homodimers (at 1.75 lM). Spironolactone antago-
nizes also other ERBB combinations, albeit with less efficacy, and
efficiently inhibits EGFR homodimer formation when stimulated by
EGF (at 1.74 lM) (Figs 3F and EV4J). Collectively, these data
suggest that spironolactone acts as a pan-ERBB family inhibitor,
which preferentially inhibits dimer formation involving EGFR or
ERBB4. In adult cortical tissues of mice, however, EGFR is not
detectably expressed (Appendix Fig S2), suggesting that ERBB4 is
the major target of the ERBB family for spironolactone in the brain.
Spironolactone reverts ERBB4 hyperphosphorylation
Dose–response assays indicated that spironolactone reduces the
phosphorylation-dependent recruitment of PIK3R1 by activated
ERBB4 (Figs 2C and 3A), prompting us to examine the phosphoryla-
tion levels reverted by spironolactone biochemically. EGFld treat-
ment of human T-47D cells that endogenously express ERBB4
induced hyperphosphorylation at Tyr1056 and Tyr1284 of ERBB4.
Addition of lapatinib completely reverted Tyr1056 and Tyr1284
phosphorylation, whereas treatment with spironolactone reduced
phosphorylation to intermediate levels (Fig 4A and B) Likewise,
spironolactone antagonized EGFld-mediated hyperphosphorylation
of transfected human ERBB4 in PC12 cells that were used in the
screen (Fig EV3D). To translate our findings into a potential thera-
peutic rationale for SZ, we utilized a transgenic mouse model, in
which Nrg1 type III is overexpressed under the control of the
neuronal Thy1.2 promoter (referred to as Nrg1-tg) and causes hyper-
phosphorylation of ERBB4 receptors in the prefrontal cortex
(Velanac et al, 2012). We tested whether phospho-ERBB4 levels
were also regulated by chronic spironolactone treatment in Nrg1-tg
mice and injected the drug for 21 consecutive days before sacrificing
the mice for biochemical analysis (Fig 4C). In lysates from mouse
prefrontal cortex, phospho-Erbb4 levels were efficiently visualized
using the p-ERBB4-Y1284 antibody (Fig 4D and E). Notably, addi-
tion of spironolactone resulted in a robust reduction of NRG1-
induced ERBB4 hyperphosphorylation. Downstream signaling
effects, as assessed by pERK and pAKT, were neither modulated by
Nrg1 overexpression, nor by spironolactone treatment. Next, we
tested whether LIM kinase 1 (LIMK1) displays regulated phosphory-
lation levels upon spironolactone treatment. LIMK1 is a non-
receptor protein serine/threonine kinase implicated in cytoskeleton
dynamics and the regulation of synaptic spine morphology and
function (Meng et al, 2002, 2004) and has been associated with
NRG1 signaling (Yin et al, 2013). Notably, phospho-Limk1 levels
were slightly upregulated in wt and markedly upregulated in
spironolactone-treated Nrg1-tg mice, suggesting that LIMK1 activity
integrates, at least in part, spironolactone’s inhibitory effect (Fig 4D
and E). Taken together, these results indicate that spironolactone
serves as an inhibitor of NRG1-mediated ERBB4 signaling.
Since NRG1-ERBB4 signaling has been shown to modulate inhibi-
tory neurotransmission (Yin et al, 2013; Agarwal et al, 2014; Mei &
Nave, 2014), we tested the impact of spironolactone treatment on
synaptic transmission in acute slices prepared from prefrontal
cortex. When we measured spontaneous inhibitory postsynaptic
currents (sIPSCs) at layer II/III pyramidal neurons, canrenone
(10 lM) showed no significant effect on sIPSC frequencies and
amplitudes (Fig 4F). In contrast, administration of spironolactone
(10 lM) caused an increase of sIPSC frequency (n = 12; P < 0.05)
and amplitude (n = 12, P < 0.05) shortly after bath application
(Fig 4G). Next, evoked IPSCs were measured in pyramidal neurons
in layer II/III of prelimbic cortex after stimulating in layer I. To
distinguish between MR and ERBB4-mediated effects by spironolac-
tone, these experiments were performed in the presence of canre-
none (10 lM), which is a more potent MR antagonist relative to
spironolactone. Under these conditions, spironolactone (5 lM)
significantly increased the eIPSC amplitude (Fig 4H), a finding also
increased by the pan-ERBB family inhibitor compound lapatinib as
control (5 lM) (Fig 4I). Together, these findings are consistent with
the hypothesis that spironolactone modulates GABAergic neuro-
transmission via ERBB4.
Chronic spironolactone treatment ameliorates SZ-relevant
behavioral endophenotypes in Nrg1-tg mice
Nrg1-tg mice exhibit SZ-relevant behavioral abnormalities, including
deficits in prepulse inhibition (PPI) (Agarwal et al, 2014), an opera-
tional measure of sensorimotor gating. In a pilot experiment, we
performed a two-arm study, in which Nrg1-tg and wt mice were
tested for PPI before and after chronic spironolactone treatment as
above (Fig EV5A). Before treatment, Nrg1-tg mice displayed PPI
deficits (Fig EV5B), in line with our previous findings (Agarwal
et al, 2014). Spironolactone treatment significantly improved PPI in
Nrg1-tg mice (Fig EV5C), but had no effect in wt controls, suggest-
ing that spironolactone modulates behavioral deficits of enhanced
NRG1-ERBB4 signaling (Fig EV5D).
Based on these results, we performed a four-arm study, in which
an independent cohort of Nrg1-tg and wt mice was tested following
spironolactone or vehicle treatment (Fig 5A). In this study, we
assessed a battery of behavioral domains with relevance for SZ,
such as motor activity, curiosity, light–dark preference, working
memory, motivation, PPI, fear memory, and pain sensitivity.
Vehicle-treated Nrg1-tg mice covered longer distances in the
open-field arena than vehicle-treated wt controls (Fig 5B and C).
This locomotor hyperactivity, however, was reverted by spironolac-
tone (Fig 5B and D). Further, Nrg1-tg mice showed, increased anxi-
ety, paralleled by higher frequency of defecation and urination
during the open-field test (Fig EV5E–G), supporting previous obser-
vations (Agarwal et al, 2014). When testing for light–dark prefer-
ence, spironolactone-treated Nrg1-tg spent more time in the light
compartment. This suggests an anxiolytic rather than a sedative
effect of spironolactone (Fig 5E), as Nrg1-tg animals and wt controls
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displayed a similar transition activity in the light–dark test
(Fig EV5H). In contrast, Nrg1-tg mice showed an increased activity
in the tail suspension test (Fig EV5I). Working memory was
assessed in the Y-maze test. Nrg1-tg mice performed significantly
less alterations than wt controls, suggesting an impaired working
memory performance in transgenics (Fig 5F). Notably, spironolac-
tone treatment rescued these deficits (Fig 5F), without influencing
the activity in the Y-maze (Fig EV5J). However, the number of
choices was higher in transgenics, supporting their hyperactivity
phenotype observed in the open-field test (Fig 5B and C).
In the contextual fear memory test, spironolactone-treated
Nrg1-tg mice displayed a non-significant reduction in freezing
(Fig EV5K), which was paralleled by significantly decreased
levels of pain sensitivity as assessed in the hot plate test
(Fig EV5L). Cue memory testing revealed neither genotype nor
treatment-dependent alterations (Fig EV5K). Moreover, spirono-
lactone treatment significantly enhanced PPI in Nrg1-tg (Fig 5G),
but not in wt mice (Fig EV5M), replicating the data obtained from
the pilot experiment (Fig EV5D).
As Nrg1 is a critical regulator for brain development, we aimed
to exclude age-related consequences on the behavioral effects
observed using a covariate analysis, which links age with test
performance. To do this, we grouped mice into juvenile
(8–11 weeks) and adult (12–16 weeks) categories, and ANCOVA
with the covariate age did not reveal an effect on the genotype-
dependent treatment response (Appendix Fig S3).
Taken together, chronic spironolactone treatment alleviates
hyperactivity, PPI and working memory deficits in Nrg1-tg mice,
findings that are paralleled by a reduction in Erbb4 hyperphosphory-
lation levels in these mice.
Discussion
To obtain repurposed drugs for schizophrenia, we have developed a
co-culture assay system mimicking several proximal aspects of
NRG1-ERBB4 signaling (Citri & Yarden, 2006; Mei & Xiong, 2008). Its
successful application in a repurposing screen with clinical
substances resulted in the identification of the MR antagonist
spironolactone as a potent ERBB4 inhibitor. The efficacy of spirono-
lactone as novel inhibitor of NRG1-ERBB4 signaling was validated in
heterologous cells with an endogenous expression of human ERBB4
and in vivo using transgenic mice, which model NRG1 overexpres-
sion and ERBB4 hyperphosphorylation linked to several endopheno-
types with relevance for SZ (Agarwal et al, 2014). We thus provide a
pharmacological proof-of-principle for targeting NRG1-ERBB4 signal-
ing in the context of SZ and exploited the opportunity to repurpose a
clinical compound, a strategy that was strongly demanded in the last
years for mental diseases (Insel, 2012). In addition, a recent study
suggested to fast track all SZ susceptibility genes, which encode
potential targets for approved drugs, for repurposing (Lencz &
Malhotra, 2015). Therefore, our multilevel approach targeting NRG1-
ERBB4 signaling that identified a hidden mode-of-action of spirono-
lactone antagonizing ERBB4 activity strongly supports this approach.
As spironolactone is a clinically safe and available substance, it
immediately qualifies for therapeutic intervention trials. Finally, the
co-culture assay is qualified for high-throughput conditions under
industry quality standards and will allow the exploratory screen of
large exploratory compound libraries.
Spironolactone inhibited the association between ERBB4 and
PIK3R1 in the split TEV-based co-culture assay, with an IC50 value
at approximately 1 lM. Our data suggest that spironolactone also
targets other ERBB family members, however, with a preference for
ERBB4. Our biochemical analysis suggests that spironolactone
shows an intermediate efficacy of ERBB4 inhibition. Notably, fine
tuning of excitation and inhibition between excitatory projection
neurons expressing NRG1 and inhibitory parvalbumin-positive
interneurons expressing ERBB4 is thought to be a critical determi-
nant of endophenotypes observed in gain- and loss-of-function
mouse models (Chen et al, 2010; Yin et al, 2013; Agarwal et al,
2014). Therefore, moderate changes in NRG1/ERBB4 activity may
be desired to achieve rebalanced signaling levels under pathological
◀ Figure 4. Spironolactone antagonizes ERBB4 phosphorylation both in in vitro and in vivo.A Spironolactone reduces ERBB4 levels. T-47D cells were stimulated with 10 ng/ml EGFld, 10 lM lapatinib and 10 lM spironolactone for 5 min as indicated. Cell
lysates were probed for ERBB4 phosphorylation levels at Tyr1056 and Tyr1284.
B Quantification of band intensities for phospho-ERBB4 levels (n = 4 per condition) shown in (A) using ImageJ. Phosphorylation levels are normalized to protein levels
of ERBB4. Data are shown as mean, and error bars represent SD; t-test, with *P = 0.0356 for p-ERBB4 (Y1056), and **P = 0.0079 for p-ERBB4 (Y1284).
C Experimental design for Western blot analysis shown in (D) and (E). Nrg1-tg and wt animals were treated daily with spironolactone (50 mg/kg, s.c.) or vehicle (n = 2
per genotype and per treatment) for 21 days.
D Spironolactone reduces phospho-Erbb4 levels in Nrg1-tg mice. Mice were treated with spironolactone for 21 days and sacrificed for Western blot analysis. Lysates
were probed with indicated antibodies.
E Quantification of band intensities for phospho-Erbb4 and phospho-Limk1 levels (n = 2 per condition) shown in (D) using ImageJ. Phosphorylation levels are normalized
to protein levels of Erbb4 and Limk1. Data are shown as mean, and error bars represent SD; t-test, with *P = 0.0330 for p-Erbb4, and *P = 0.0201 for p-Limk1.
F Canrenone (applied as 10 lM) showed no effects on frequencies and amplitudes of sIPSCs in pyramidal neurons of the prefrontal cortex (PFC). Representative traces
of sIPSCs (upper) and a histogram of mean sIPSC (lower) are shown for both before and after addition of canrenone.
G Spironolactone (applied as 10 lM) significantly increases frequencies (n = 12; *P = 0.0454) and amplitudes (n = 12, *P = 0.0478) of sIPSCs in pyramidal neurons of
PFC. Representative traces of sIPSCs (upper) and a histogram of mean sIPSC (lower) are shown for both before and after addition of spironolactone.
H Spironolactone increases amplitudes of evoked IPSCs in pyramidal neurons of PFC (n = 15, *P = 0.0286). Spironolactone (5 lM) was applied in the presence of
canrenone (10 lM).
I Lapatinib increases amplitudes of evoked IPSCs in pyramidal neurons of PFC (n = 15, *P = 0.0124). Lapatinib was applied at 5 lM. Arrow indicates an evoked IPSC
stimulus.
Data information: For (H, I), sample recording (upper) and a histogram of averaged eIPSC (lower) is shown for both before and after drug application. For (F–I), the
numbers displayed inside the histogram bars indicate the number of recorded slices/number of animals. Data are shown as mean, and error bars represent SD (for B, E)
and SEM (for F–I); paired t-test, with *P ≤ 0.05; Spiro, spironolactone; Canre, canrenone; Lap, lapatinib.
Source data are available online for this figure.
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conditions. We found that the chronic administration of spironolac-
tone to Nrg1-tg mice reverted Erbb4 hyperphosphorylation and
largely rescued hyperactivity (considered as a surrogate marker for
positive symptoms in SZ), PPI deficits and working memory impair-
ments. Importantly, behavior in wild-type mice remained largely
unaffected by chronic spironolactone treatment. Spironolactone, but
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Figure 5. Chronic spironolactone treatment ameliorates deficits of behavioral endophenotypes in Nrg1-tg mice.
A Experimental design. Nrg1-tg and wt animals were treated daily with spironolactone (50 mg/kg, s.c.) or vehicle (n = 12 per genotype and per treatment) for
3 weeks, followed by behavioral phenotyping using the tests as indicated. Spironolactone or vehicle treatment was continued throughout the phenotyping
phase.
B Nrg1-tg mice travelled longer distances in the open-field arena (effect of genotype F1,44 = 10.53; P = 0.0022; two-way ANOVA). Bonferroni post hoc analysis revealed a
significant genotype-dependent difference between vehicle-treated groups (**P = 0.0044) but not in spironolactone-treated groups (P = 0.3783). Genotype differences
were abolished upon spironolactone treatment.
C When vehicle-treated animals were analyzed in 1-min intervals, transgenic mice showed an increased activity throughout the entire test (effect of genotype F1,22 = 9.27;
P = 0.0060; two-way ANOVA), most prominent in intervals 2, 7, and 8 (*P = 0.0427, *P = 0.0385, and ***P = 0.000036, respectively, Bonferroni post hoc test).
D There was no significant difference between the genotypes when treated with spironolactone (effect of genotype F1,22 = 2.19; P = 0.1535; two-way ANOVA). However,
the interaction of genotype and treatment was significant (F9,198 = 1.94; P = 0.0481; two-way ANOVA).
E Nrg1-tg mice treated with spironolactone spent more time in the light compartment during the light–dark test (interaction gene × treatment F1,41 = 4.90;
P = 0.0324; two-way ANOVA, and *P = 0.0219, Bonferroni post hoc test).
F In the Y-maze test, transgenic mice performed less alterations (effect of genotype F1,44 = 11.50; P = 0.0015; two-way ANOVA). The Bonferroni test confirmed this
phenotype in vehicle-treated groups (**P = 0.0011), but not in spironolactone-treated animals (P = 0.5950). Spironolactone treatment had a significant effect on the
number of alterations (F1,44 = 4.12; P = 0.0484; two-way ANOVA).
G Spironolactone treatment significantly enhanced PPI in Nrg1-tg mice (effect of treatment F1,21 = 5.07; *P = 0.0325; two-way repeated-measures ANOVA).
Data information: Data are shown as mean, and error bars represent SEM. Spiro, spironolactone; Veh, vehicle. n = 12 per genotype and treatment with an exception of
(E) (Nrg1-tg vehicle, n = 11; Nrg1-tg Spiro, n = 10; wt vehicle, n = 12; wt Spiro, n = 12) and (G) (Nrg1-tg vehicle, n = 11; Nrg1-tg Spiro, n = 12.
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not canrenone, enhanced inhibitory neurotransmission when
applied acutely to cortical slices of wild-type mice, suggesting an
ERBB4-mediated mechanism. Likewise, the ERBB4 kinase inhibitor
lapatinib caused similarly increased IPSCs within the same experi-
mental model. Increased amplitudes of mIPSCs have also been
observed in conditional Nrg1 loss-of-function mutants, most likely
as a consequence of reduced activity of ERBB4 in inhibitory neurons
(Agarwal et al, 2014). In conditional ERBB4 mutants, however,
mIPSC frequencies were reduced in the hippocampus (Fazzari et al,
2010). A recent study reports that NRG2, a close relative of NRG1, is
expressed in inhibitory interneurons and activates ERBB4 cell-
autonomously, causing a downregulation of NMDA receptor activity
in these cells (Vullhorst et al, 2015). In such a scenario, inhibition
of ERBB4 activity may indeed increase IPSCs, a hypothesis fitting to
our observations, for both spironolactone and lapatinib control
treatments. Overall, these findings indicate that altered NRG1/
ERBB4 signaling modulates inhibitory signaling, although different
adaptations may prevail in different brain regions and genetic
models as well as pharmacological treatments.
Our biochemical analysis implicates LIMK1 signaling, but not
ERK1/2 nor AKT1 as potential downstream effectors of spironolac-
tone treatment in Nrg1-tg mice. As a non-receptor protein serine/
threonine kinase, LIMK regulates synaptic spine morphology and
function by modulating cytoskeleton dynamics (Meng et al, 2002,
2004; Bennett, 2011). Further, LIMK1 has been linked to NRG1
signaling and SZ-relevant endophenotypes in a Nrg1-tg mouse
model (Yin et al, 2013). We show that phospho-LIMK1 levels were
upregulated in Nrg1-tg mice treated with spironolactone suggesting
that LIMK1 activity may possibly integrate spironolactone’s inhibi-
tory effect by promoting spine enlargement, and thus synapse
formation, through controlling actin cytoskeleton dynamics. Nrg1-tg
animals display subtle structural changes related to spine morphol-
ogy, that is, the number of bifurcated spines is increased (Agarwal
et al, 2014). Therefore, it might be possible that spironolactone
treatment reverts this structural endophenotype. Nonetheless, the
increased levels of p-LIMK1 rather favor a mechanism compensating
for the structural changes in Nrg1-tg mice, which may underlie
network disturbances in these animals, by stimulating structural
plasticity via increased LIMK1 activity. To further explore the mode-
of-action of spironolactone in the future, its impact on structural
plasticity should be addressed in additional studies.
Spironolactone has been developed as MR antagonist and was
clinically applied for decades as a potent and safe diuretic (Ogden
et al, 1961). As brain-expressed corticoid receptors are implicated in
modulating the stress response, spironolactone treatment has been
tested in the context of depression and was shown to increase moti-
vation and curiosity in mice (Wu et al, 2012). Moreover, anxiety
was partially improved in a small group of patients suffering from
bipolar disorder (Juruena et al, 2009) in good agreement with our
finding that spironolactone affects anxiety-related behavior in Nrg1-
tg mice. Acute spironolactone administration to healthy human
volunteers, however, reduced memory retrieval (Zhou et al, 2011;
Rimmele et al, 2013) and reportedly impaired recent fear memory
formation in mice (Zhou et al, 2011). Upon chronic administration
of spironolactone, however, we could not observe any detrimental
effects on cognitive performance in fear and working memory tests
in wild-type mice. However, spironolactone-treated Nrg1-tg mice
displayed a slightly reduced level of fear memory, which may be
partially dependent on anxiolytic actions of spironolactone or
decreased pain sensitivity in transgenic mice. Nonetheless, working
memory deficits of Nrg1-tg mice were rescued upon spironolactone
treatment.
Structure-function analysis using spironolactone metabolites and
second-generation analogues revealed that the intact structure of
spironolactone is paramount for inhibiting ERBB4 signaling activity.
We speculate that other structural modifications of spironolactone
may improve its selectivity for ERBB4 binding and concomitant inhi-
bition. Spironolactone may therefore also serve as a template for a
lead optimization process, which could produce a new molecular
entity with improved characteristics to inhibit ERBB4 signaling and
avoiding potentially adverse effects on the MR. Nonetheless, given
our observations and the safety profile of spironolactone, a clinical
study might be warranted to assess the chronic effects of spironolac-
tone treatment in SZ patients.
Materials and Methods
Plasmids
Gateway recombination cloning (Life Technologies) was applied for
generating plasmids. Each ORF cloned was PCR-amplified using the
Pwo proofreading DNA polymerase (Roche) and BP-recombined
into the pDONR/Zeo plasmid (Life Technologies) to yield an entry
vector, which was control-digested using BsrGI to release the insert,
and sequence-verified. The following human ORFs were cloned
using cDNA image clones ordered from Source BioScience: ERBB4
transcript variant JM-a/CYT-1 (Accession: BC112199), PIK3R1
(BC094795), GRB2 transcript variant 1 (BC000631), SHC1 transcript
variant 2 (BC014158), STAT5A (BC027036), and SRC transcription
variant 1 (BC051270). For EGFR, ERBB2, and ERBB3, entry vectors
were obtained from the human CCSB kinase collection available
from Addgene (Johannessen et al, 2010). Entry vectors were LR-
recombined into split TEV destination vectors [either pcDNA_attR1-
ORF-attR2-NTEV-tevS-GV-2xHA_DEST or pTag4C_attR1-ORF-attR2-
CTEV-2xHA_DEST, plasmids were described in detail before (Wehr
et al, 2006)] to yield expression vectors, which were control-
digested using BsrGI. The plasmids for Nrg1 type I b1a and rat Nrg1
type III b1a have been described before (Wehr et al, 2006).
The oligonucleotides used for cloning are shown in the
Appendix Table S2.
Cell culture
PC12 Tet-Off cells (Clontech, 631134, termed PC12 cells for simplic-
ity) and their derivatives stably expressing Nrg1 were cultured in
low glucose DMEM medium (1 g/l, Lonza) supplemented with 10%
FCS, 5% HS, 50 lg penicillin, 50 lg streptomycin and GlutaMAX
(Life Technologies) at 37°C, and 5% CO2. T-47D cells (ATCC:HTB-
133) were grown RPMI-1640 (Life Technologies) supplemented with
0.2 units/ml bovine insulin (Sigma), 10% FCS, 50 lg penicillin,
50 lg streptomycin and GlutaMAX (all Life Technologies) at 37°C,
and 5% CO2. PC12 cells were grown on poly-L-lysine-coated
surfaces for both maintenance and experiments; T-47D cells were
only grown on poly-L-lysine-coated surfaces for experiments. Cell
lines were negative for mycoplasma contamination.
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Generation of PC12 cells stably expressing Nrg1
1 Mio PC12 cells were either transfected with 10 lg of a Nrg1 type I
b1a plasmid or Nrg1 type III b1a plasmid using Lipofectamine 2000.
Following an initial expression of 24 h, 400 lg/ml G418 was applied
to select stable clones as each Nrg1 plasmid harbors a neomycin
resistance gene for selection in mammalian cells. After 2 weeks of
culturing, visible PC12 cell clones were transferred into a single well
of a 24-well plate. Following to a recovery and expansion phase,
stable Nrg1 expression was validated in a split TEV-based ERBB4-
PIK3R1 co-culture assay. Positive clones were also verified by
Western blot analysis.
Protein lysates and Western blotting
PC12 cells were transfected with indicated plasmids using Lipo-
fectamine 2000 (Life Technologies). After 24 h of expression,
cells were treated as indicated and lysed in a 1% Triton-X lysis
buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1% Triton X-100,
1 mM EGTA) supplemented with 10 mM NaF, 1 mM Na2VO4,
1 mM ZnCl2 4.5 mM Na4P207, as phosphatase inhibitors, and the
complete protease inhibitor cocktail (Roche). Lysates from T-47D
cells were analyzed for endogenous proteins only. For the analy-
sis of cytosolic proteins, cell extracts were spun for 10 min at
4°C at 17,000 g.
For the biochemical analysis of spironolactone-treated mice (for
a precise description of the injection paradigm, see subheading
“Mouse behavior analysis”, “Spironolactone treatment”), vehicle
control or spironolactone was subcutaneously injected daily for
21 days into age-matched (11–13 weeks) male mice prior to prepa-
ration of the mouse prefrontal cortex (n = 2 per genotype and treat-
ment). For the generation of lysates, the isolated tissue was
immediately placed into cooled (4°C) sucrose buffer (320 mM
sucrose, 10 mM Tris–HCl, 1 mM NaHCO3, 1 mM MgCl2, supple-
mented with 10 mM NaF, 1 mM Na2VO4, 1 mM ZnCl2, 4.5 mM
Na4P207 as phosphatase inhibitors, and the complete protease inhi-
bitor cocktail (Roche)), homogenized using an ultra-turrax (IKA
GmbH, Staufen, Germany), sonicated (3 pulses for 10 s), and dena-
tured for 10 min at 70°C in LDS sample buffer.
Protein gels were run using the Mini-PROTEAN Tetra Elec-
trophoresis System (Bio-Rad), and gels were blotted using the
Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad). Detection
of proteins was performed by Western blot analysis using chemi-
luminescence (Western Lightning Plus-ECL, PerkinElmer).
Western blots were probed with antibodies at dilutions as shown
in the Appendix Table S3. Each blot was replicated two times.
Western blots were densitometrically quantified using ImageJ
following the protocol openly accessible at lukemiller.org (http://
lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-
with-image-j/).
Immunofluorescence staining of PC12 cells
1 Mio PC12 cells were plated per well onto poly-L-lysine (PLL)-
coated coverslips in a 6-well plate at day 1. At day 2, cells were
transfected with ERBB4-NTEV-tevs-GV or ERBB4_1-685-NTEV-tevS-
GV. At day 3, cells were gently washed twice by adding and remov-
ing 1× TBS (50 ll per coverslip), fixed in cold 4% PFA for 10 min,
washed twice with 1× TBS, and permeabilized in TBS/0.1% Triton
X-100 for 5 min. Then, cells were washed again three times in 1×
TBS and blocked in blocking buffer (3% BSA, 0.1% Triton X-100 in
1× TBS) for 1 h at room temperature. Primary antibodies diluted in
blocking buffer and cells were incubated for 1 h at room tempera-
ture. Following three washes in TBS, cells were incubated with a
secondary antibody (Alexa 594 anti-rat, 1:500, Abcam, ab150160)
diluted in blocking buffer for 1 h at room temperature. Coverslips
were washed three times in 1× PBS, once quickly dipped into ddH2O
to remove traces of salt, mounted on microscope slides, and sealed
with ProLong Gold Antifade Mountant with Dapi (ThermoFisher
Scienctific, P36935). Slides were stored at 4°C before imaged on a
Zeiss Observer Z.1 microscope.
Compound screening and validation
Cell-based split TEV assay to monitor ERBB4 activity
The split TEV method is based on the functional complementation
of two previously inactive TEV protease fragments denoted NTEV
and CTEV fused to interacting proteins. It has been shown to
robustly and sensitively quantify protein–protein interactions and
receptor activities, as proven before for the ERBB4 receptor and the
regulatory adapter subunits of the PI3K, PIK3R1, and PIK3R2 (Wehr
et al, 2006, 2008). Recently, the split TEV method was also success-
fully applied to genomewide RNAi screening in Drosophila cell
culture, supporting its applicability to high-throughput applications
(Wehr et al, 2013).
For our HTS-compatible split TEV assay approach, human full-
length ERBB4-Cyt1 was fused to the NTEV fragment, a TEV
protease cleavage site (tevS) and the artificial co-transcriptional
activator Gal4-VP16 (ERBB4-NTEV-tevS-GV); human PIK3R1 was
fused to the CTEV fragment (PIK3R1-CTEV) (Fig 1A). Upon
ERBB4 activation, PIK3R1 is recruited to the receptor resulting in
a reconstituted protease activity that cleaves off GV. In turn,
released GV translocates to the nucleus and binds to upstream
activating sequences (UAS) to activate the transcription of a fire-
fly luciferase reporter gene (Fig 1A). A constitutively expressed
Renilla luciferase driven under the control of the human thymi-
dine kinase (TK) promoter was used as control to address off-
target effects related to toxicity.
Compound library
For small molecule screening, the NIH-NCC Clinical Collection
library (sets NCC-003 and NCC-201) was used containing 727 small
molecules that are FDA-approved and have a history in clinical
applications (www.nihclinicalcollection.com). A Hamilton Labstar
robot connected to 37 and 4°C incubators for cell incubation and
compound storage and application (Cytomat automated incubator,
ThermoScientific) and to a luciferase reader (Berthold Technologies)
was used to automatically perform the screening. Batch 1 (com-
pounds 1–320) was run in quadruplets, batch 2 (compounds 321–
727) in triplicates. Each batch was screened three times.
Transfection of cells
To equally transfect large amounts of cells, PC12 cells were trans-
fected with the split TEV assay components in solution. For one 96-
well plate, 4 × 106 PC12 cells were harvested and diluted in 5 ml
assay medium (phenol red-free DMEM (low glucose, Life
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Technologies), 10% FCS, 5% HS, no antibiotics). The split TEV
assay plasmids (2 lg pcDNA3_ERBB4-NTEV-tevS-GV-2xHA, 2 lg
pTag4C_PIK3R1-CTEV-2xHA, 2 lg p5xUAS_firefly luciferase, 2 lg
pTK_Renilla luciferase, and 0.5 lg pECFP-C1 for examining trans-
fection efficiency) were diluted in 2.5 ml Opti-MEM (Life Techno-
logies) and vortexed. In parallel, 20 ll of the transfection reagent
Lipofectamine 2000 was diluted in 2.5 ml Opti-MEM and vortexed.
Both Opti-MEM aliquots were mixed, vortexed, and incubated for
20 min at room temperature, followed by carefully mixing the
DNA/Lipofectamine/Opti-MEM solution with the PC12 cells and
incubating the cell suspension at 37°C and 5% CO2 for 2 h without
shaking.
Plating the cells
For plating of one 96-well plate, 10 ml suspension, containing the
4 × 106 in solution-transfected cells, was placed in the bubble
paddle reservoir of the Hamilton Cellstar robot. 100 ll was seeded
per 96-well using the 96-tip pipetting head. The homogeneity of the
cell suspension was guaranteed over time by mild stirring using the
paddling device inside the reservoir. For five plates each, 50 ml of
additional cell suspension was used to allow for losses of inaccessi-
ble volume. After seeding, plates were transferred and stored in the
Cytomat device at 37°C and 5% CO2.
Addition of compounds
The cells were allowed to express the plasmids for 24 h before
compounds were added. Proper expression and transfection effi-
ciency were verified by ECFP expression on a clear control plate.
The compounds were applied in a final concentration of 10 lM
using DMSO as diluent. Sixteen positions per 96-well plate (i.e.,
columns A and H) were reserved for controls; in detail, four wells
each were taken for positive controls (stimulated with 10 ng/ml
EGFld (Reprokine, RKQ02297) in DMSO, 96-well positions A1 to
D1), baseline controls (DMSO only, 96-well positions E1 to H1),
negative controls I (100 nM CI-1033 (Canertinib dihydrochloride,
Axon, 1433) in DMSO, 96-well positions A12-D12), and negative
controls II (10 lM lapatinib (Lapatinib ditosylate, Axon, 1395) in
DMSO, 96-well positions E12 to H12). Thirty minutes later, 10,000
Nrg1-expressing PC12 cells in 100 ll assay medium were seeded on
top. 24 h after addition of the compounds, the cells were lysed using
40 ll Passive Lysis buffer (Promega) and subjected to a Dual
Luciferase Assay (Promega) according to the manufacturer’s
instructions. The data were analyzed in R Bioconductor using the
package cellHTS2 (http://www.bioconductor.org/packages/devel/
bioc/html/cellHTS2.html), assessed using the z-score, and visual-
ized using the program Mondrian (http://stats.math.uni-augsb
urg.de/mondrian/).
Dose–response luciferase assays for validation
Individually re-screened candidates were validated using a dose–
response assay. PC12 cells were batch-transfected as described in
the section “Transfection of cells”, manually plated, and incubated
for 24 h at 37°C and 5% CO2. Candidate small molecules were
prepared in a series of dilutions using DMSO as diluent and ranging
from 0.0001 to 100 lM at final concentrations, thus covering at least
five orders of magnitude. Candidate dilutions were added, followed
by the addition of 10,000 Nrg1-expressing cells in 100 ll volume
30 min later. Cells were lysed in 40 ll Passive Lysis Buffer and
analyzed in a Dual Luciferase Assay. Data were analyzed in Excel
and GraphPad Prism. For single-culture assays that used EGFld as
stimulus, 100 ll assay medium containing EGFld (f.c. 10 ng/ml)
was administered. The following candidates were analyzed in dose–
response assays: spironolactone (Sigma-Aldrich, S3378), eplen-
renone (Sigma-Aldrich, E6657), canrenone (Santa Cruz Biotechnol-
ogy, sc-205616), 7a-thiomethyl-spironolactone (Santa Cruz
Biotechnology, sc-207187). Dose–response assays were run in six
replicates per concentration and repeated at least two times. Data
are shown as mean, and error bars represent SEM.
Electrophysiology
300-lm-thick transverse slices comprising the medial prefrontal
cortex (mPFC) area were prepared from 7- to 8-week-old C57Bl/6
mice as described previously (Teng et al, 2013; Agarwal et al,
2014). All recordings were performed in cortical layer V projection
neurons. The bath solution consisted of oxygenated artificial cere-
brospinal fluid (ACSF) containing NaCl 126 mM, KCl 3 mM,
NaH2PO4 1.25 mM, MgSO4 1 mM, NaHCO3 26 mM, CaCl2 2 mM,
glucose 10 mM, and the pH 7.2 adjusted with NaOH. Spontaneous
GABAergic inhibitory postsynaptic currents (sIPSC) and evoked
GABAergic inhibitory postsynaptic currents (eIPSC) were
recorded at a holding potential of 70 mV in the presence of
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 lM) and DL-2-
amino-5-phosphonovaleric acid (D-APV, 50 lM). Glass pipettes
were filled with the solution containing: KCl 140 mM, MgCl2 2 mM,
CaCl2 1 mM, Na2GTP 0.5 mM, Na2ATP 4 mM, EGTA 10 mM,
HEPES 10 mM. Patches with a series resistance of > 25 MO, a
membrane resistance of < 0.8 GO, or leak currents of > 150 pA
were excluded. Biphasic rectangular electric pulses (10 ms, 100–
300 lA) were applied to layer I of the prelimbic area of mPFC
through another glass pipette filled with ACSF. Synaptic currents
were acquired at 20 kHz and filtered at 6 kHz, with a Digidata 1440
ADC-converter coupled to a Multiclamp 700B amplifier (Molecular
Devices, USA). Data acquisition was performed using pClamp10
software (Molecular Devices). MiniAnalysis 6.0.9 (Synaptosoft Inc.,
Decatur, USA) and pClamp10.1 were used for amplitude and
frequency analysis of sIPSCs and eIPSCs, respectively. Paired
Student’s t-test was used for statistical analysis.
Mouse behavior analysis
For behavioral testing, age-matched male mice (8–16 weeks) on
C57Bl/6 background that constitutively overexpress the 2xHA-
tagged Nrg1 type III b1a isoform (Nrg1-tg) under the control of the
mouse Thy1.2 promoter (Velanac et al, 2012) and their wild-type
(wt) littermates as controls were used. Animals were group-housed
in the same ventilated sound-attenuated rooms under a 12-h light/
12-h dark schedule (lights on at 8:00 am) at an ambient temperature
of 21°C with food and water available ad libitum. One week prior to
experiments, mice were separated into single cages and habituated
to the experimental rooms. To minimize the influence of the circa-
dian rhythm on drug actions, the treatment groups were analyzed at
balanced time points during the light phase. The investigators for
behavioral tests were blind to genotypes and/or spironolactone
administration. All animal experiments were conducted in accor-
dance with NIH principles of laboratory animal care and were
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approved by the Government of Lower Saxony, Germany, in accor-
dance with the German Animal Protection Law.
Spironolactone treatment
50 mg of Spironolactone (Sigma-Aldrich) was initially dissolved in
DMSO and suspended in 10 ml of 0.9% NaCl, 1% DMSO, and
0.002% Tween20. Spironolactone (5 mg/ml) and a vehicle control
(0.9% NaCl, 1% DMSO, and 0.002% Tween20) were subcuta-
neously injected with a 50 mg/kg dose daily (e.g., corresponding to
0.3 ml injection volume of a mouse with 30 g weight) for 3 weeks
prior to behavioral testing (n = 12 per genotype and per treatment).
Treatment was continued throughout the behavioral analysis
period. To avoid injection-induced stress prior to behavioral testing,
mice were injected in the afternoon, after the entire cohort has
completed the behavioral paradigm.
Calculation of spironolactone dosage
The calculated daily dosage of 50 mg/kg/day spironolactone for
mice is based on the following assumptions. Patients are routinely
treated with 400 mg/day spironolactone (Aldactone 100, Riemser
Pharma; spironolactone 100, Ratiopharm). Dosages of 50 to
100 mg/day were administered to patients in long-term treatments
(Juruena et al, 2009). The dosage of 400 mg/80 kg patient body
weight per day is equal to 5 mg/kg/day. Human doses are
converted to mouse doses using the body surface area normalization
method, which integrates various aspects of biological parameters
including basal metabolism, blood volume, caloric expenditure, and
oxygen utilization (Reagan-Shaw et al, 2008). For the calculation of
the mouse dose (mg/kg), the human dose (mg/kg) is multiplied by
the human Km/mouse Km, where the human Km = 37 and the mouse
Km = 3. Therefore, mice should be treated with a 12-fold higher
dose. The chosen dosage of 50 mg/kg/day is slightly below the
calculated maximum dose of 61.7 mg/kg/day [(400 mg/80 kg)*
(37/3)/day]. The lC50 of spironolactone is > 1,000 mg/kg/day.
Spironolactone is FDA-approved, used in patients for decades, and
shows no major side effect in treated mice.
Behavioral tests applied for mouse behavior analysis
Open field and hole board Spontaneous locomotor activity was
verified in the open-field test using a Plexiglas box (45 × 45 ×
55 cm). The same test arena was modified with a floor insert
containing 16 symmetrically allocated holes for the hole board test.
During a 10-min testing session, mouse behavior was monitored by
infrared sensors and recorded by the ActiMot software (TSE, Bad
Homburg, Germany). Levels of urination (scored in events) and
defecation (scored as feci in events) were determined manually
during the open-field test.
Light–dark preference The light–dark preference test was
conducted in a plastic chamber divided into two compartments of
same size, with one having black and the second one having trans-
parent Plexiglas walls. A door-like opening in the center of the sepa-
rating wall allowed transitions between both compartments. For
testing, each mouse was placed into the light compartment facing
away from the door and left undisturbed. The latency to enter the
dark compartment, the time spent in the dark compartment, and
the number of crossings between the compartments were monitored
for 5 min using the AnyMaze software. Mice that did not enter the
dark compartment within 10 min were excluded from the experi-
ment. After each session, the chambers were cleaned with 70%
ethanol.
Y-maze The assessment of working memory was performed using
an in-house made Y-shaped runway. Animals were placed individu-
ally into the Y-maze facing the wall and allowed to explore the maze
for 10 min. The experiment was video recorded. The number of arm
choices (as a measure of activity) and the percent of alterations
(choices of a “novel” arm, i.e., when animals chose a different arm
as before is regarded as a measure of working memory) were scored
and analyzed. To avoid any olfactory cues, the apparatus was
cleaned with 70% ethanol between animals.
Tail suspension test Mice were manually suspended upside down
for 6 min by attaching them to a fixed rod using an adhesive tape
positioned at the tip of the tail. The escape motivation of a mouse
was measured as the time spent active, video recorded, and scored
offline.
Prepulse inhibition (PPI) The startle response was measured using a
two test cabinet (SR-LAB, San Diego Instruments) using a protocol
as described in Brzo´zka et al (2010).
Fear conditioning Fear memory assessment that is measured by
freezing behavior was performed using the Ugo Basile Fear Condi-
tioning System (Varese, Italy). For conditioning, mice were placed
into the animal box (furnished with a stainless shock grid floor and
striped black-white walls) and positioned into an isolation cubicle
equipped with a lamp, a loudspeaker and infrared camera. For
conditioning, striped black-white walls were inserted into the
animal box. The conditioning and fear memory assessment were
performed as described in Brzo´zka et al (2010).
Hot plate Pain sensitivity was measured in the hot plate test.
Animals were placed onto a metal plate preheated to 52°C. The
latency to the first reaction (hind paw licking or jumping) was
scored manually. Immediately after the first response, mice were
placed onto another metal plate (not heated) to allow cooling their
paws.
Statistical analysis
Statistical significance was determined using Microsoft Excel, IBM
SPSS Statistics v22 and GraphPad Prism 5.0 software. Data are
presented as means  SD or SEM as indicated (n ≥ 3, for luciferase
assays n = 6). For behavioral experiments, Student’s t-tests were
used for comparing two data samples. If the experimental setup
required a paired data analysis, paired Student’s t-test or paired
Wilcoxon signed ranks test was used for comparing two normally or
not-normally distributed data samples, respectively. Two-way
ANOVA with Bonferroni post hoc test was used for the analysis of
three or more samples. Two-way ANCOVA was used for the age-
corrected analyses of open-field, Y-maze and light–dark preference
tests. Repeated-measures ANOVA was used to analyze the effects of
treatment in the PPI analyses. The robustness of cell-based assays
was assessed using the Z’ factor. Data from screening were analyzed
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using the cellHTS2 package available for R and evaluated using the
z-score.
Expanded View for this article is available online.
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